Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Objectives: To evaluate the human abuse potential of pitolisant, a selective histamine 3 (H3)-receptor antagonist/inverse agonist recently approved by the US Food and Drug Administration for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Methods: Nondependent, recreational stimulant users able to distinguish phentermine HCl 60 mg from placebo in a drug discrimination test were randomized in a four-period, double-blind, crossover design to receive single doses of pitolisant 35.6 mg (therapeutic dose), pitolisant 213.6 mg (supratherapeutic dose), phentermine HCl 60 mg, and placebo. The primary endpoint was maximum effect (Emax) on the 100-point Drug Liking (“at this moment”) visual analog scale. Results: In 38 study completers (73.7% male; 65.8% white; mean age, 33.3 years), mean Drug Liking Emax was significantly greater for phentermine versus pitolisant 35.6 mg (mean difference, 21.4; p < 0.0001) and pitolisant 213.6 mg (mean difference, 19.7; p < 0.0001). Drug Liking Emax was similar for pitolisant (both doses) and placebo. Similarly, for key secondary measures of Overall Drug Liking and willingness to Take Drug Again, mean Emax scores were significantly greater for phentermine versus pitolisant (both doses) and similar for pitolisant (both doses) versus placebo. The incidence of adverse events was 82.1% after phentermine HCl 60 mg, 72.5% after pitolisant 213.6 mg, 47.5% after pitolisant 35.6 mg, and 48.8% after placebo administration. Conclusions: In this study, pitolisant demonstrated significantly lower potential for abuse compared with phentermine and an overall profile similar to placebo; this suggests a low risk of abuse for pitolisant. Clinical Trial Registration: ClinicalTrials.gov NCT03152123. Determination of the abuse potential of pitolisant in healthy, nondependent recreational stimulant users. https://clinicaltrials.gov/ct2/show/NCT03152123.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“Other safety assessments included vital signs measurements, physical examination findings, clinical laboratory test results, electrocardiogram parameters, and Columbia-Suicide Severity Rating Scale (C-SSRS) score [35].”
MethodThe International Classification of Sleep Disorders: Diagnostic and Coding Manual
Daroff, R. B. (1991) · Neurology · doi:10.1212/wnl.41.1.160 · Cited by 5,014
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733 · cited 1×
“amphetamines, opioids, ethanol, nicotine, and cocaine) [25, 26] and wake-promoting agents (i.”
The International Classification of Sleep Disorders
Greenblatt, D. W. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530270020006 · Cited by 1,559
The brain on drugs: from reward to addiction
Volkow, N. D., & Morales, M. (2015) · Cell · doi:10.1016/j.cell.2015.07.046 · Cited by 1,306 · cited 1×
“amphetamines, opioids, ethanol, nicotine, and cocaine) [25, 26] and wake-promoting agents (i.”
Histamine in the Nervous System
Haas, H. L., Sergeeva, O. A., & Selbach, O. (2008) · Physiological Reviews · doi:10.1152/physrev.00043.2007 · Cited by 1,228 · cited 1×
“Histamine activates wake-promoting neurons including norepinephrine neurons in the locus coeruleus, acetylcholine neurons in the pons and forebrain, and serotonin neurons in the dorsal raphe nucleus [58]; however, as noted above, histamine does not increase dopamine release in the nucleus accumbens [24, 27].”
BackgroundMartin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 943 · cited 13×
“Peak scores on the ARCI scales were significantly different for pitolisant (both doses) compared with phentermine and not different for pitolisant relative to placebo (Table 3), with the exception of the dysphoria (LSD) scale, on which mean Emax for pitolisant 213.6 mg was significantly greater than that for placebo a…”
BackgroundMethodInfluentialMethylphenidate: Its Pharmacology and Uses
CHALLMAN, T. D., & LIPSKY, J. J. (2000) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)64618-1 · Cited by 553
Volkow, N. D., Fowler, J. S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Wang, G.-J., Jayne, M., Hooker, J. M., Wong, C., et al. (2009) · JAMA · doi:10.1001/jama.2009.351 · Cited by 529 · cited 1×
“the human nucleus accumbens, a brain region associated with rewarding effects and abuse [50].”
Background
Cited by
Update on Persistent Excessive Daytime Sleepiness in OSA
Javaheri, S., & Javaheri, S. (2020) · Chest · doi:10.1016/j.chest.2020.02.036 · Cited by 122
Metadata
- Authors
- Setnik, B., McDonnell, M., Mills, C., Scart-Grès, C., Robert, P., Dayno, J. M., & Schwartz, J.-C.
- Venue
- Sleep
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10-18
- Volume
- 43
- Issue
- 4
- ISSN
- 0161-8105 (ISSN-L)
- 1550-9109
- OpenAlex
- W2981226218
- Cited by
- 189
- References
- 46
- FWCI
- 24.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. https://app.cochat.ai/papers/10.1093/sleep/zsz252
- The paper
- Setnik, B., McDonnell, M., Mills, C., Scart-Grès, C., Robert, P., Dayno, J. M., & Schwartz, J.-C. (2020). Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Sleep. https://doi.org/10.1093/sleep/zsz252
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.